Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: Effects on prognosis and cell invasion

International Journal of Cancer

Volumn 127, Issue 1, 2010, Pages 21-31

  Siu, Michelle K Y ^a   Wong, Esther S Y ^a   Chan, Hoi Yan ^a   Kong, Daniel S H ^a   Woo, Nina W S ^a   Tam, Kar Fai ^a   Ngan, Hextan Y S ^a   Chan, Queeny K Y ^a   Chan, Dominic C W ^a   Chan, Kelvin Y K ^a   Cheung, Annie N Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cell invasion; Ovarian cancer; Pak1; Pak2; Phosphorylation; Prognosis

Indexed keywords

CARBOPLATIN; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 2; PACLITAXEL; SERINE; THREONINE; VASCULOTROPIN; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; PAK2 PROTEIN, HUMAN; PRIMER DNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRADING; CARCINOGENESIS; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY; OVARY CARCINOMA; OVARY CYST; OVARY DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SAMPLE; CANCER INVASION; CELL LINE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL PROLIFERATION; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; P21-ACTIVATED KINASES; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 77953465926     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25005     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16.
3. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
4. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 2003;72:743-81.
5. Vadlamudi RK, Kumar R. P21-activated kinases in human cancer. Cancer Metastasis Rev 2003;22: 385-93.
6. Kumar R, Hung MC. Signaling intricacies take center stage in cancer cells. Cancer Res 2005;65:2511-15.
7. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006;6:459-71.
8. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003;163:985-92.
9. Brown LA, Kalloger SE, Miller MA, Shih IE M, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 2008;47:481-9.
10. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Lohrs U, Amann G, Diebold J. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 2006;126:101-9.
11. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 2006;25:2931-6.
12. Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, Hess KR, Aldape KD, Kondo S, Kumar R, Kondo Y. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res 2007;13:6603-9.
13. Coniglio SJ, Zavarella S, Symons MH. Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol Cell Biol 2008;28:4162-72.
14. Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, Cheung AN. Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. Am J Pathol 2008;173:1165-72.
15. Stofega MR, Sanders LC, Gardiner EM, Bokoch GM. Constitutive p21-activated kinase (PAK) activation in breast cancer cells as a result of mislocalization of PAK to focal adhesions. Mol Biol Cell 2004;15:2965-77.
16. Chan QK, Ngan HY, Ip PP, Liu VW, Xue WC, Cheung AN. Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis - a differential expression and functional analysis. Carcinogenesis 2009;30:114-21.
17. Liao X, Siu MK, Au CW, Wong E, Chan HY, Ip P, Ngan HY, Cheung AN. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009;30:131-40.
18. Shen DH, Chan KY, Khoo US, Ngan HY, Xue WC, Chiu PM, Ip P, Cheung AN. Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis 2005;26:855-63.
19. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
20. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, Chan DC, Chan QK, Cheung AN. Tyrosine kinase B receptor and BDNF expression in ovarian cancers - effect on cell migration, angiogenesis and clinical outcome. Cancer Lett 2009;281:151-61.
21. Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN, Edmondson RJ. Androgenrelated expression of G-proteins in ovarian cancer. Br J Cancer 2009;101:498-503.
22. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:2233-9.
23. Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, Li AS, Khoo US, Cheung AN. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer 2008;123:296-302. (Pubitemid 351842013)
24. Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W, Rubin SC, Coukos G. The oncogene phosphatidylinositol 30-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 2003;63:4225-31.
25. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 1999;93:3379-90.
26. Helenius MA, Saramaki OR, Linja MJ, Tammela TL, Visakorpi T. Amplification of urokinase gene in prostate cancer. Cancer Res 2001;61:5340-4.
27. Zhou HY, Pon YL, Wong AS. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology 2007;148:5195-208.
28. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factorregulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006;118:879-88.
29. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Jr., Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994;56:552-9.
30. Young TN, Rodriguez GC, Rinehart AR, Bast RC, Jr, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996;62:89-99.
31. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 2004;279:8567-76.
32. Sowter HM, Corps AN, Smith SK. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer 1999;83:476-80.
33. Halperin R, Hadas E, Langer R, Bukovsky I, Schneider D. Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer. Int J Gynecol Cancer 1999;9:502-7.
34. Wang J, Lin L, Parkash V, Schwartz PE, Lauchlan SC, Zheng W. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int J Cancer 2003;103:328-34.
35. Yang CQ, Chan KY, Ngan HY, Khoo US, Chiu PM, Chan QK, Xue WC, Cheung AN. Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis 2006;27:1502-6.
36. Davidson B, Shih IM, Wang TL. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. Hum Pathol 2008;39:1630-6.
37. Banerjee M, Worth D, Prowse DM, Nikolic M. Pak1 phosphorylation on t212 affects microtubules in cells undergoing mitosis. Curr Biol 2002;12:1233-9.
38. Sundberg-Smith LJ, Doherty JT, Mack CP, Taylor JM. Adhesion stimulates direct PAK1/ERK2 association and leads to ERK-dependent PAK1 Thr212 phosphorylation. J Biol Chem 2005;280:2055-64.
39. Thiel DA, Reeder MK, Pfaff A, Coleman TR, Sells MA, Chernoff J. Cell cycle-regulated phosphorylation of p21-activated kinase 1. Curr Biol 2002;12:1227-32.
40. Rayala SK, Kumar R. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity. Biomed Pharmacother 2007;61:408-11.
41. Singh RR, Song C, Yang Z, Kumar R. Nuclear localization and chromatin targets of p21-activated kinase 1. J Biol Chem 2005;280:18130-7.
42. Zhou GL, Zhuo Y, King CC, Fryer BH, Bokoch GM, Field J. Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration. Mol Cell Biol 2003;23:8058-69.
43. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106. (Pubitemid 27270925)
44. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 2004;279:1422-8.
45. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008;15:322-31.
46. Eswaran J, Soundararajan M, Kumar R, Knapp S. UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci 2008;33:394-403.